FrancophonIA/ELRC3.0 huggingface dataset:
English: Hepsera has been studied in two main studies, in which it was compared with placebo (a dummy treatment).
Estonian: Hepserat uuriti kahes põhiuuringus, milles seda võrreldi platseeboga (näiva ravimiga).
English: Because the hepatitis B virus can become resistant to Hepsera, the doctor should only consider prescribing Hepsera if other treatments that are less likely to lead to resistance cannot be used;
Estonian: Et B-hepatiidi virus võib muutuda Hepsera suhtes resistentseks, tohib arst määrata Hepserat ainult juhul, kui muid raviviise, mis tekitavad resistentsust vähem tõenäoliselt, ei saa kasutada;
English: For more information about treatment with Hepsera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Hepseraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Hepsera?
Estonian: Mis on Hepsera?
English: The duration of treatment depends on the patient's condition and response to treatment.
Estonian: Ravi kestus sõltub patsiendi seisundist ja ravivastusest, mida tuleb kontrollida iga kuue kuu järel.
English: To reduce the risk of resistance, Hepsera must be used in combination with another anti-hepatitis B medicine that does not cause resistance in the same way as Hepsera.
Estonian: Resistentsuse riski vähendamiseks tuleb Hepserat kasutada koos muu B-hepatiidi ravimiga, mis tekitab resistentsust teisel viisil kui Hepsera.
English: This is a summary of the European public assessment report (EPAR) for Hepsera.
Estonian: See on ravimi Hepsera Euroopa avaliku hindamisaruande kokkuvõte.
English: The first study included 511 patients who were ‘HBeAg positive' (infected with the common type of the hepatitis B virus) and the second included 184 patients who were ‘HBeAg negative' (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
Estonian: Esimeses uuringus osales 511 HBeAg-positiivset patsienti (nakatunud tavalise B-hepatiidi viirusega) ja teises 184 HBeAg-negatiivset patsienti (nakatunud muteerunud (muutunud) viirusega, mille tulemusena tekkiv krooniline B-hepatiit allub ravile raskemini).
English: Hepsera is not recommended for use in patients with severe kidney disease or who are on dialysis (a blood clearing technique) - its use should only be considered in these patients if its potential benefits are greater than its potential risks.
Estonian: Hepserat ei soovitata kasutada patsientidel, kellel on raske neeruhaigus või kes saavad dialüüsravi (teatud verepuhastusmeetod) - ravimi kasutamist võib kaaluda ainult juhul, kui võimalik kasu on kaasnevatest riskidest suurem.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Hepsera.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: • decompensated liver disease (when the liver is damaged and does not function normally.
Estonian: • dekompenseeritud maksahaigusega patsientidel (maks on kahjustatud ning selle talitlus on häiritud).
English: Hepsera was more effective than placebo in slowing down the progression of liver disease.
Estonian: Hepsera aeglustas platseebost efektiivsemalt maksahaiguse progresseerumist.
English: Why has Hepsera been approved?
Estonian: Miks Hepsera heaks kiideti?
English: Adefovir is an antiviral belonging to the class ‘nucleoside analogues'.
Estonian: Adefoviir on nukleosiidianaloogide klassi kuuluv viirusevastane aine.
English: • compensated liver disease (when the liver is damaged but functions normally), who also show signs that the virus is still multiplying, and have signs of liver damage (raised levels of the liver enzyme ‘alanine aminotransferase' [ALT] and signs of damage when liver tissue is examined under a microscope).
Estonian: • kompenseeritud maksahaigusega patsientidel (maks on kahjustatud, kuid selle talitlus on normaalne), kellel on viiruse edasise replitseerumise ning maksakahjustuse nähud (maksaensüümi alaniinaminotransferaasi (ALT) sisalduse suurenemine veres ja maksakoe mikroskoopuuringutel ilmnevad kahjustusnähud).
English: Hepsera must not be used in people who are hypersensitive (allergic) to adefovir dipivoxil or any of the other ingredients.
Estonian: Hepserat ei tohi kasutada patsiendid, kes on adefoviirdipivoksiili või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Hepsera is used to treat adults with chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis B virus).
Estonian: Hepserat kasutatakse kroonilise (pikaajalise) B-hepatiidi (B-hepatiidi viiruse nakkusest põhjustatud maksapõletiku) raviks täiskasvanutel.
English: Hepsera is a medicine that contains the active substance adefovir dipivoxil.
Estonian: Hepsera on ravim, mis sisaldab toimeainena adefoviirdipivoksiili.
English: The most common side effects with Hepsera (seen in more than 1 patient in 10) are raised creatinine (a marker of kidney problems) and asthenia (weakness).
Estonian: Hepsera kõige sagedamad kõrvalnähud (esinenud rohkem kui 1 patsiendil 10st) on kreatiniini (neeruhäirete marker) sisalduse suurenemine veres ja asteenia (nõrkus).
English: For the full list of all side effects reported with Hepsera, see the package leaflet.
Estonian: Hepsera kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Patients who have problems with their kidneys should take Hepsera less frequently.
Estonian: Neeruhäiretega patsiendid peaksid võtma Hepserat harvemini.
English: What is the risk associated with Hepsera?
Estonian: Mis riskid Hepseraga kaasnevad?
English: Adefovir interferes with the action of a viral enzyme called DNA polymerase, which is involved in the formation of viral DNA.
Estonian: Adefoviir häirib viiruse DNA moodustumisel osaleva viiruseensüümi DNA-polümeraasi toimet.
English: Other information about Hepsera
Estonian: Muu teave Hepsera kohta
English: What is Hepsera used for?
Estonian: Milleks Hepserat kasutatakse?
English: In both studies, the effectiveness was measured by looking at how the liver damage had evolved after 48 weeks of treatment using a liver biopsy (when a sample of liver tissue is taken and examined under a microscope).
Estonian: Mõlemas uuringus hinnati efektiivsust muutuste järgi maksas, mis olid tekkinud pärast 48-nädalast ravi.
English: What benefit has Hepsera shown during the studies?
Estonian: Milles seisneb uuringute põhjal Hepsera kasulikkus?
English: How is Hepsera used?
Estonian: Kuidas Hepserat kasutatakse?
English: The active substance in Hepsera, adefovir dipivoxil, is a ‘prodrug' that is converted into adefovir in the body.
Estonian: Hepsera toimeaine adefoviirdipivoksiil on eelravim, mis muundub organismis adefoviiriks.
English: How does Hepsera work?
Estonian: Kuidas Hepsera toimib?
English: It is used in patients with:
Estonian: Seda kasutatakse
English: Treatment with Hepsera should be started by a doctor who has experience in the management of chronic hepatitis B. The recommended dose is 10 mg once a day.
Estonian: Ravi Hepseraga peab alustama kroonilise B-hepatiidi ravis kogenud arst.
English: How has Hepsera been studied?
Estonian: Kuidas Hepserat uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Hepsera on retseptiravim.
English: This procedure started on 21 August 2006 and ended on 20 October 2006.
Estonian: See menetlus algas 21. augustil 2006 ja lõppes 20. oktoobril 2006.
English: In conclusion, CVMP is of the opinion that:
Estonian: Kokkuvõttes on veterinaarravimite komitee arvamusel, et:
English: 7.e.13 Hungary
Estonian: 7.e.13 Ungari
English: (Immunisation schedules are given in the product information.)
Estonian: (Immuniseerimise ajakavad on esitatud tooteteabes)
English: The procedure started on 13 March
Estonian: Menetlus algas 13. märtsil 2006.
English: One dose = 2 ml
Estonian: Üks annus = 2 ml
English: CY-1665 Nicosia Cyprus
Estonian: CY-1665 Nicosia Küpros
English: 50 ELISA units, inducing ≥ 4.6 log2 VN units
Estonian: 50 ELISA ühikut, indutseerib ≥ 4,6 log2 VN ühikut
English: SI-1000 Ljubljana Slovenija
Estonian: SI-1000 Ljubljana Sloveenia
English: Member State Applicant or Marketing Authorisation Holder
Estonian: Liikmesriik Taotleja või müügiloa hoidja Ravimi väljamõeldud nimetus
English: The first renewal procedure for the vaccine was finalised in June 2004.
Estonian: Vaktsiini müügiloa esimene pikendamismenetlus lõppes 2004. aasta juunis.
English: It is worthy of note that the first EU marketing authorisation for Bovilis BVD was granted in 1998, and the vaccine is currently authorised in 14 EU Member States.
Estonian: On märkimisväärne, et ELi esimene Bovilis BVD müügiluba väljastati aastal 1998 ning vaktsiinil on praegu müügiluba 14 ELi liikmesriigis.
English: B-2800 Mechelen Belgium
Estonian: B-2800 Mechelen Belgia
English: Per 2 ml dose:
Estonian: 2 ml annuses:
English: The initial mutual recognition procedure was finalised on 24 June 1999, and 11 other Member States authorised the product at this time.
Estonian: Algne vastastikuse tunnustamise menetlus jõudis lõpule 24. juunil 1999 ning tol korral andsid vaktsiinile müügiloa veel 11 liikmesriiki.
English: There is always a small risk of extraneous agent contamination from a variety of sources.
Estonian: Väike väliste haigustekitajatega saastumise oht mitmesugustest allikatest on alati olemas.
English: The factors which determine the safety of a product are the measures applied in the production and control procedures.
Estonian: Tegurid, mis määravad vaktsiini ohutuse, on selle tootmisel ja kontrollimisel rakendatavad meetmed.
English: The extra testing (which requires the use of animals) would therefore be a disproportionate measure when balanced against the positive effects which can be obtained for this vaccine.
Estonian: Seega oleks täiendav kontrollimine (milleks on vaja kasutada loomi) ebaproportsionaalne meede, võrreldes selle vaktsiiniga saadavate võimalike positiivsete tulemustega.
English: On the contrary it is known that extremely high numbers of samples must be tested in order to detect a low level of defects.
Estonian: On vastupidi teada, et väga väheste olemasolevate puuduste tuvastamiseks on vaja kontrollida väga suurel arvul proove.
English: ES-37080 Salamanca Spain
Estonian: ES-37080 Salamanca Hispaania
English: Wybrzeze Gdynskie 6c PL-01-531 Warszawa Poland
Estonian: Wybrzeze Gdynskie 6c PL-01-531 Warszawa Poola
English: Bovilis BVD was first authorised in Germany on 6 May 1998 (as Bovilis BVD-MD).
Estonian: Bovilis BVD-le anti algselt müügiluba 6. mail 1998. aastal Saksamaal (nimetusega Bovilis BVD-MD).
English: DK-2740 Skovlunde Denmark
Estonian: DK-2740 Skovlunde Taani
English: In March 2006 Intervet then submitted an application for a marketing authorisation for this vaccine following a repeat use mutual recognition procedure, with Germany acting as Reference Member State, for Denmark, Poland, Slovakia and Slovenia.
Estonian: Seejärel esitas Intervet 2006. aasta märtsis taotluse müügiloa saamiseks sellele vaktsiinile Taanis, Poolas, Slovakkias ja Sloveenias vastavalt korduvtaotlemise vastastikuse tunnustamise menetluse reeglitele, nii et viiteliikmesriigiks oli Saksamaa.
English: 3, Paparigopoulou Street GR-152 32 Halandri Athens Greece
Estonian: 3, Paparigopoulou Street GR-152 32 Halandri Athens Kreeka
English: Intervet Bulgaria EOOD 7, Iskarsko shoes blvd BG-1528 Sofia Bulgaria
Estonian: Intervet Bulgaria EOOD 7, Iskarsko shoes blvd BG-1528 Sofia Bulgaaria
English: FR-49071 Beaucouzé Cedex France
Estonian: FR-49071 Beaucouzé Cedex Prantsusmaa
English: DE-85716 Unterschleissheim Germany
Estonian: D-85716 Unterschleissheim Saksamaa
English: Based on the current requirements and the relevant safeguards (e.g., GMP) the CVMP concludes that the Applicant has taken adequate measures to guarantee the quality and safety of Bovilis BVD.
Estonian: Lähtudes praegustest nõuetest ja asjakohastest kaitsemeetmetest (nt hea tootmistava) leiab veterinaarravimite komitee, et taotleja poolt rakendatavad meetmed on Bovilis BVD kvaliteedi ja ohutuse tagamiseks piisavad.
English: There are many years of experience with the use of this vaccine, and there are no known adverse reactions associated with the vaccine.
Estonian: Selle vaktsiini kasutamisega on olemas aastatepikkune kogemus ning teadaolevalt ei seostata sellega mitte mingisuguseid kõrvaltoimeid.
English: Foot and Mouth virus is virtually exotic to Western Europe and Bluetongue, although of a recent change in status, is not ubiquitous or endemic in the majority of the EU, so for these 2 agents the practical risks should be lower.
Estonian: Suu- ja sõrataudi viirus on Lääne-Euroopas praktiliselt eksootiline, ja sinikeelehaigus, mille asend üldises päevakorras on küll hiljuti muutunud, pole ELis enamasti üldlevinud ega endeemiline, ning seega peaksid nendest kahest haigustekitajast tulenevad praktilised riskid olema väiksemad.
English: At day 90 of the MRP, 2 August 2006, Denmark could not agree to the granting of a marketing authorization as they considered the product to present a potential serious risk for animal health.
Estonian: Taani ei saanud vastastikuse tunnustamise menetluse 90. päeval, 2. augustil 2006, müügiloa andmisega nõustuda, sest leidis, et vaktsiin võib tõsiselt ohustada loomade tervist.
English: Considering all the measures taken, it is very unlikely that any contamination of Bovilis BVD could firstly occur, and secondly that such contamination would eventually lead to seroconversion, even in a small number of vaccinated animals.
Estonian: Arvestades kõiki rakendatavaid meetmeid on väga ebatõenäoline esiteks Bovilis BVD saastumine ja teiseks serokonversiooni tekkimine sellise saastumise tagajärjel, isegi vähestel vaktsineeritud loomadel.
English: The matter was referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures, CMD(v), for a 60 day procedure in accordance with Article 33(1) of Directive 2001/82/EC, as amended.
Estonian: Küsimus esildati veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühmale (CMD(v)) 60-päevase menetluse läbiviimiseks vastavalt muudetud direktiivi 2001/82/EÜ artikli 33 lõikele 1.
English: With regard to the potential benefit or otherwise from conducting additional tests, it is known that the efficiency of final batch testing in revealing defects is highly variable, depending on the type of defect, and that it is preferable to build quality into the whole process rather than rely on end product testing.
Estonian: Seoses küsimusega, kas täiendavast kontrollist võiks olla kasu või mitte, on teada, et valmispartiide kontrollimise efektiivsus puuduste tuvastamisel võib olenevalt konkreetsest puudusest suuresti varieeruda ning et on eelistatavam lülitada kvaliteedikontroll protsessi tervikuna, selle asemel et loota valmisravimi kontrollimisele.
English: • extraneous agents testing of raw materials are carried out according to the relevant requirements
Estonian: • tooraineid kontrollitakse väliste haigustekitajate suhtes vastavate nõuete kohaselt;
English: Luxembourg Intervet Belgium Bedrijvenlaan 7
Estonian: Luksemburg Intervet Belgium Bedrijvenlaan 7
English: The benefits of Bovilis BVD vaccine are accepted.
Estonian: Vaktsiini Bovilis BVD kasulikkus on aktsepteeritud.
English: Belgium Intervet Belgium Bedrijvenlaan 7
Estonian: Intervet Belgium Bedrijvenlaan 7
English: Denmark considers that the proposed testing regime to demonstrate freedom from extraneous agents is insufficient to ensure that Bovilis BVD would not interfere with their national eradication campaigns for certain animal diseases and that therefore the benefit: risk assessment for Bovilis BVD is negative and authorisation of the product would represent a potential serious risk to animal health.
Estonian: Taani leiab, et väliste haigustekitajate mittesisaldumise tõendamiseks kavandatud kontrollisüsteem ei ole piisav tagamaks, et Bovilis BVD ei häiri riigis läbiviidavaid loomade teatavate haiguste eradikatsiooni kampaaniaid, mistõttu on Bovilis BVD riski ja kasulikkuse suhe negatiivne ning vaktsiinile müügiloa andmine võib ohustada tõsiselt loomade tervist.
English: ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER
Estonian: I LISA RAVIMI NIMETUS, RAVIMVORM, TUGEVUS, SIHTLOOMALIIK, MANUSTAMISVIISID JA MÜÜGILOA HOIDJA
English: The CVMP has concluded that the risk/benefit for Bovilis BVD is favourable.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et Bovilis BVD riski ja kasulikkuse suhe on positiivne.
English: The added value of retesting for this feature in inactivated viral vaccines is extremely small.
Estonian: Täiendav kasu inaktiveeritud viirusvaktsiinide selle omaduse suhtes uuesti kontrollimisest on äärmiselt väike.
English: • the production of Bovilis BVD vaccine is in compliance with GMP requirements
Estonian: • vaktsiini Bovilis BVD tootmine vastab hea tootmistava nõuetele;
English: No scientific arguments are available concerning how the additional testing would minimise the risk of possible seroconversion induced by the vaccine.
Estonian: Teaduslikke põhjendusi selle kohta, kuidas oleks täiendava kontrollimise abil võimalik vähendada miinimumini ohtu, et vaktsiin võib kutsuda esile serokonversiooni, pole avaldatud.
English: The risk of accidental contamination with FMDV, IBRV, BLV and BTV is concluded to be low; consequently the risk of seroconversion against the listed agents is also concluded to be low.
Estonian: On jõutud järeldusele, et suu- ja sõrataudiviirusega (FMDV), veiste nakkava rinotrahheiidi viirusega (IBRV), veiste leukeemiaviirusega (BLV) ja sinikeeleviirusega (BTV) juhusliku saastumise oht on väike ning järelikult on väike ka serokonversiooni oht loetletud haigustekitajate suhtes.
English: Therefore the Danish testing requirement is considered to be unjustified.
Estonian: Seetõttu on komitee seisukohal, et Taani esitatud kontrollimisnõue ei ole põhjendatud.
English: As the likelihood of contamination of Bovilis BVD vaccine, and the subsequent probability of seroconversion by such contaminants is extremely low, the advantage of additional final product testing for extraneous agents (serological method) is considered to be negligible.
Estonian: Kuna vaktsiini Bovilis BVD saastumise ning seejärgse vastavatest saasteainetest tingitud serokonversiooni tõenäosus on äärmiselt väike, on valmisravimi täiendava väliste haigustekitajate suhtes (seroloogilisel meetodil) kontrollimise kasutegur komitee arvates mittearvestatav.
English: The probability that any such contamination would be identified in the test proposed by the Danish Medicines Agency is even smaller.
Estonian: Veelgi ebatõenäolisem on, et niisugune saastumine Taani Ravimiameti poolt soovitatava kontrollimise käigus tuvastatakse.
English: BLV and IBRV are more ubiquitous but the measures summarised below have generally been accepted in the majority of member states to be adequate to ensure negligible risk.
Estonian: Veiste leukeemiaviirus ja veiste nakkav rinotrahheiit on rohkem levinud, kuid enamikus liikmesriikides tunnustatakse üldiselt, et allpool kokkuvõtlikult esitatud meetmed on väga madala riskitaseme tagamiseks piisavad.
English: SK-040 01 Kosice Slovak Republic Tel: +421 (55) 676 9405 Fax: +421 (55) 676 9873
Estonian: SK-040 01 Kosice Slovaki Vabariik Tel: +421 (55) 676 9405 Faks: +421 (55) 676 9873
English: The Marketing Authorisation Holder should provide all supporting data to justify a positive benefit-risk ratio for the treated animal.
Estonian: Müügiloa hoidja peab esitama kõik olemasolevad andmed tõestamaks, et selle vaktsiini riski ja kasulikkuse suhe on ravitava looma seisukohast positiivne.
English: Consequently Germany notified the EMEA, on 31 October 2006, that the CMD(v) failed to reach an agreement regarding Bovilis BVD.
Estonian: Seetõttu teatas Saksamaa 31. oktoobril 2006 Euroopa Ravimiametile, et veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordineerimisrühm ei saavutanud Bovilis BVD suhtes kokkulepet.
English: Although the consequences of an accidental seroconversion against the listed extraneous agents would damage the animal health status of a country free from the four specified diseases, the benefit: risk evaluation remains positive due to the low risk of contamination of the product.
Estonian: Kuigi loetletud väliste haigustekitajate suhtes juhusliku serokonversiooni tagajärjed kahjustaksid loomade tervise taset riigis, kus nimetatud nelja haigust ei esine, on vaktsiini vähese saastumisohu tõttu selle kasulikkuse ja riski suhe siiski positiivne.
English: The CMD(v) could not reach an agreement by day 60 of this procedure, as to where Denmark maintained their concerns.
Estonian: Menetluse 60. päevaks koordineerimisrühm selles küsimuses, mis Taanile endiselt muret valmistas, ühisele seisukohale ei jõudnud.
English: During its meeting of November 2006, the CVMP started a referral procedure under Article 33(4) of Directive 2001/82/EC as amended for Bovilis BVD.
Estonian: Oma 2006. aasta novembri koosolekul algatas veterinaarravimite komitee Bovilis BVD suhtes esildismenetluse vastavalt muudetud direktiivi 2001/82/EÜ artikli 33 lõikele 4.
English: Therefore the requested additional specified extraneous testing requirement is scientifically not justified for Bovilis BVD.
Estonian: Seetõttu ei ole taotletav nõue Bovilis BVD täiendavaks kontrollimiseks väliste haigustekitajate suhtes teaduslikult põhjendatud.
English: Pursuant to Article 33(4) of Council Directive 2001/82/EC, as amended, the matter has been referred to CVMP.
Estonian: Vastavalt muudetud direktiivi 2001/82/EÜ artikli 33 lõikele 4 esildati see küsimus läbivaatamiseks veterinaarravimite komiteele.
English: Czech Republic Tel: +420 (2) 333 440 25 Fax: +420 (2) 333 440 22
Estonian: Tšehhi Vabariik Tel: +420 (2) 333 440 25 Faks: +420 (2) 333 440 22
English: In general, the absence of extraneous agents in vaccines can be ensured by: GMP compliance of the production system Extraneous agents testing of raw materials Extraneous agents testing of batches of finished product, if required.
Estonian: Väliste haigustekitajate puudumine vaktsiinides on üldiselt võimalik tagada järgmiste meetmetega: tootmissüsteemi vastavus heale tootmistavale; toorainete kontrollimine väliste haigustekitajate suhtes; vajadusel valmisravimi partiide kontrollimine väliste haigustekitajate suhtes.
English: Fax: + 31 485 587 653
Estonian: Faks: + 31 485 587 653
English: Fax: +39 (02) 516 866 87
Estonian: Faks: +39 (02) 516 866 87
English: Fax: +32 (15) 436 733
Estonian: Faks: +32 (15) 436 733
English: • extraneous agents testing of finished batches of Bovilis BVD for FMDV, BLV, BTV and IBRV is not required in the relevant monographs
Estonian: • Bovilis BVD valmispartiide kontrollimist väliste haigustekitajate - suu- ja sõrataudi viiruse, veiste leukeemiaviiruse, sinikeelehaiguse ega veiste nakkava rinotrahheiidi suhtes vastavates monograafiates ei nõuta.
English: Intervet S.A.
Estonian: Prantsusmaa Intervet S.A.
English: Suspension for injection
Estonian: Lihasesiseseks süstimiseks
English: Strength
Estonian: Veis
English: Representative of Intervet in the Slovak Rep.
Estonian: Interveti esindaja Slovaki Vabariigis
English: Intervet International B.V. Wim de Korverstraat 35 NL-5831 AN Boxmeer The Netherlands Tel: + 31 485 587 652
Estonian: NL-5831 AN Boxmeer Madalmaad
English: It is available as tablets (20 mg; 40 and 80 mg).
Estonian: Seda turustatakse tablettidena (20 mg, 40 mg ja 80 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Telmisartan Actavis on 30 September 2010.
Estonian: Euroopa Komisjon andis Telmisartan Actavise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. septembril 2010.
English: Telmisartan Actavis telmisartan
Estonian: Telmisartan Actavis telmisartaan
English: If the target blood
Estonian: Kui see ei